CCM
VTYX

CAAS Capital Management’s Ventyx Biosciences VTYX Stock Holding History

CAAS Capital Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,000
Closed -$2.03M – 979
2022
Q3 		$2.03M Buy
+60,000
New +$1.33M 0.1% 280

Other funds holding VTYX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAAS Capital Management's VTYX Position: Q4 2022 in Review

CAAS Capital Management sold out of Ventyx Biosciences (VTYX) in Q4 2022, closing a stake of 60,000 shares — an estimated $2.03M sold.

CAAS Capital Management first reported a position in VTYX in Q3 2022 and held it in 1 quarter. The position peaked at $2.03M in Q3 2022. 125 funds tracked by Wall St. Rank hold VTYX as of Q4 2022.

  • CAAS Capital Management reported no remaining Ventyx Biosciences position as of Q4 2022 after selling out during the quarter.
  • CAAS Capital Management sold 60,000 Ventyx Biosciences shares in Q4 2022, an estimated $2.03M.
  • CAAS Capital Management first reported a position in Ventyx Biosciences in Q3 2022 and held it in 1 quarter.
  • CAAS Capital Management's Ventyx Biosciences position peaked at $2.03M in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.